H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7
Buy Rating Reiterated for Puma Biotechnology Amid Promising Phase 2 Trial and Strategic FDA Engagement
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
TD Cowen Maintains Puma Biotechnology(PBYI.US) With Hold Rating, Maintains Target Price $4
Barclays Maintains Puma Biotechnology(PBYI.US) With Sell Rating, Maintains Target Price $2
Barclays Reaffirms Their Sell Rating on Puma Biotechnology (PBYI)
TD Cowen Maintains Puma Biotechnology(PBYI.US) With Hold Rating, Maintains Target Price $4
Puma Biotechnology's Positive Trajectory Amid Mixed Signals: Hold Rating Maintained
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7
Puma Biotechnology: A Buy Rating Reinforced by Strong Q2 Performance and Solid Prospects for Flagship Product Nerlynx
Barclays Maintains Puma Biotechnology(PBYI.US) With Sell Rating, Maintains Target Price $2
Barclays Sticks to Its Sell Rating for Puma Biotechnology (PBYI)
TD Cowen Maintains Puma Biotechnology(PBYI.US) With Hold Rating, Maintains Target Price $4
Puma Biotechnology: Hold Rating Justified by Sales Concerns and Financial Strain
Puma Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
H.C. Wainwright Maintains Puma Biotechnology(PBYI.US) With Buy Rating, Maintains Target Price $7